Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...

TRIANA Biomedicines has entered into a strategic collaboration and licensing agreement with US pharma giant Pfizer to ...

Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 ...

Pfizer will apply Triana Biomedicines’ target-first and proximity-first discovery platform to discover molecular glue degraders for unspecified “multiple” targets in oncology and several other disease ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH ...

LEXINGTON, MA / ACCESSWIRE / October 15, 2024 / TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on building a target-first molecular glue discovery pipeline for ...

Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working ...

Two former Pfizer executives drawn into a campaign by activist investor Starboard Value to shake up the company have withdrawn their support for the plan. Pfizer's ex-chair and chief executive Ian ...

(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...

David Risinger’s rating is based on a combination of factors including recent developments within Pfizer’s leadership and the actions of activist investors. Risinger acknowledges the support ...

4 "HYMPAVZI is Pfizer’s second hemophilia treatment to receive FDA approval this year and is the latest meaningful scientific advancement in our more than 40-year commitment to improve care for ...

The FDA granted the approval of Hympavzi to Pfizer Inc. (Image Credits: Pixabay) The U.S. Food and Drug Administration (USFDA) approved Hympavzi (marstacimab-hncq) for patients suffering from ...